


EMBRYSIGHT

A pioneering a game-changing AI technology that analyzes thousands of embryonic developmental parameters, to perform a pre-symptomatic diagnosis of autism as early as in utero

Deliverables: Naming, Communication's strategy, Branding & Visual Concept & investor deck







embryosight

Detecting Autism. In Utero.


Enabling early intervention
through early detection



Map
170dB/C 5
Persist Off
2D Opt:FSCT
Fr Rate:Surv



Enabling early intervention
through early detection



Map
170dB/C 5
Persist Off
2D Opt:FSCT
Fr Rate:Surv




Revealing the invisible
dance of embryos




- 0
- 1
- 2
- 3
- 4
- 5
- 6

Map
170dB/C 5
Persist Off
2D Opt:FSCT
Fr Rate:Surv



Detecting ASD in time for a
life-changing intervention




Map
170dB/C 5
Persist Off
2D Opt:FSCT
Fr Rate:Surv




Detecting ASD in time for a **life-changing intervention**



Map
170dB/C 5
Persist Off
2D Opt:FSCT
Fr Rate:Surv




Unique Features




Prenatal classification of autism severity

FP<5% based on prenatal info
FP<2% with additional postnatal info



Customizable delivery

delivering the results as per
the parent's preferences



Scalable and accessible

A cloud-based, automated solution
that relies only on available data

Ultrasound data

Including a variety of classic anatomical characteristics and complex parameters that are invisible to the human eye


Map
170dB/C 5
Persist Off
2D Opt:FSCT
Fr Rate:Surv



Ultrasound data

Including a variety of classic anatomical characteristics and complex parameters that are invisible to the human eye


Map
170dB/C 5
Persist Off
2D Opt:FSCT
Fr Rate:Surv



Additional data

Including any non-ultrasound data that can be relevant, including medical and familial history, and socioeconomic info

Map
170dB/C 5
Persist Off
2D Opt:FSCT
Fr Rate:Surv



Enabling early intervention through early detection



Map
170dB/C 5
Persist Off
2D Opt FSGT
Fr Rate Surv



EmbrySight is pioneering a game-changing AI tool to diagnose autism in utero, identifying its unique developmental signature in order to enable optimal, time-critical interventions soon after birth, by analyzing thousands of parameters extracted from routine fetal ultrasound together with medical and non-medical data



Unique Features




Prenatal classification
of autism severity

FP<5% based on prenatal info
FP<2% with additional postnatal info



Customizable delivery

delivering the results as per
the parent's preferences



Scalable and accessible

A cloud-based, automated solution
that relies only on available data



1 in 44

Children Is diagnosed
with autism

25%-50%

Of Autistic children are
Non-verbal and have
severe symptoms

>80%

Of ASD cases cannot
be diagnosed by
genetic testing




Autism detection


The unique developmental signature is used to provide an exact detection of ASD presence and severity

More +

Unique benefits to all stakeholders



Families



Government and payers



Health providers







“Pearlcom played a pivotal role in crafting the marketing identity of Embrysight, from conceptualizing the company's name and designing a captivating brand identity to creating an impressive investor deck and pitch. With their vast background in medical imaging and expertise in MedTech, Pearlcom's dedicated team provided invaluable strategic marketing insights that enabled us to effectively communicate our mission of early autism diagnosis. We are grateful for their partnership and highly recommend Pearlcom to any medtech startup seeking to make a meaningful impact.”

Onn Sever | CEO & CO-FOUNDER
EmbrySight | **T.** +972 52-469-3939